SPX-104

N/A

Report date: 2025/01/26 17:29:42

Base Information

Drug NameSPX-104
Drug Alias Nameanti-LILRB2 monoclonal antibody (Sparx/Peking University)anti-leukocyte immunoglobulin like receptor B2 monoclonal antibody (Sparx/Peking University)LILRB2 checkpoint inhibitor (Sparx/Peking University)SPX-104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsLung NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPeking University
China Registration ClassN/A

Develop Information

Active CompaniesSparX Biopharmaceutical CorpPeking University
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A